STUDY OF TETRATHIOMOLYBDATE (TM) AS A DECOPPERING AND ANTIANGIOGENESIS OF CANCER

转移性实体瘤患者的治疗通常非常有限 由于细胞减灭化疗的累积毒性， 耐药性 保持或减小尺寸的新方法 转移性肿瘤的最佳治疗方法是抑制新血管生长到 肿瘤床或血管生成。 铜已被证明是一个必要条件 对于动物的血管生成，我们试图确定是否减少 铜导致实体瘤缩小或减缓其生长。 最 已知的铜的有效抑制剂是四硫代钼酸盐（TM），开发 用于治疗患有威尔逊氏病的患者， 组织中极高的铜含量 而TM已经 安全地用于患有威尔逊氏病的人，其毒性 转移性癌症患者的特征尚不清楚。 我们提出了一个 TM在转移性实体瘤患者中的I期研究 用尽了其他治疗方法。

Patients with metastatic solid tumors often have very limited treatment options due to cumulative toxicity of cytoreductive chemotherapy and drug resistance. A new approach to the maintenance or reduction in size of metastatic tumors is inhibition of new blood vessel growth into the tumor bed or angiogenesis. Copper has been shown to be a requirement for angiogenesis in animals, we seek to determine whether decrease in copper causes shrinkage or slows growth of solid tumors. The most potent inhibitor of copper known is Tetrathiomolybdate (TM), developed at the UM for the treatment of patients with Wilson's disease who suffer from extremely high levels of copper in tissues. Whereas TM has been safely administered to humans with Wilson's disease, its toxicity profile in patients with metastatic cancer is not known. We propose a Phase I study of TM in patients with metastatic solid tumors who have exhausted other treatment options.